ImmuneXcite is a privately held biotech company based in Lexington, Mass., that is developing the next generation of immune-activating, anti-tumor biotherapeutics against a wide range of cancers. The company’s near-term business objective is to select a lead program within its discovery pipeline and then advance this program into the clinic by early 2018. Given the potential breadth of the company’s technology, its intention is to leverage the strength of the mAbXcite platform with a select group of biopharmaceutical partners. In 2015, ImmuneXcite established undisclosed early-stage collaborations with two of the leading biopharmaceutical companies in the immuno-oncology space.